The different response rates to BM come from the good efficiency of EGFR-TKI in passing through the blood brain barrier and targeting the BM of NSCLC patients harboring sensitive EGFR mutations [59, 60]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.